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Abstract
The importance of innate immune cells in HIV-1 pathogenesis and protection has been highlighted by the role of natural
killer (NK) cells in the containment of viral replication. Use of peripheral blood mononuclear cells (PBMC) in immunologic
studies provides both HIV-1 target cells (ie. CD4+ T cells), as well as anti-HIV-1 effector cells, such as NK cells. In this study, NK
and other immune cell populations were analyzed in HIV-negative donor PBMC for an impact on the anti-HIV activity of
polyclonal and monoclonal antibodies. NK cell percentages were significantly higher in donor PBMC that supported lower
levels of viral replication. While the percentage of NK cells was not directly associated with neutralization titers, NK cell-
depletion significantly diminished the antiviral antibody activity by up to three logs, and polymorphisms in NK killer
immunoglobulin receptor (KIR) and FccRIIIa alleles appear to be associated with this affect. These findings demonstrate that
NK cells and NK cell receptor polymorphisms may influence assessment of traditional HIV-1 neutralization in a platform
where antibody is continuously present. This format appears to simultaneously assess conventional entry inhibition
(neutralization) and non-neutralizing antibody-dependent HIV inhibition, which may provide the opportunity to delineate
the dominant antibody function(s) in polyclonal vaccine responses.
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Introduction
The results of the RV144 Phase III vaccine trial conducted in
Thailand using a canarypox-vectored prime and gp120 envelope
subunit boost, demonstrated modest protection (31.2% efficacy)
against HIV-1 acquisition [1]. It has been hypothesized that this
effect may be due to protective antibodies. The vaccine elicited
anti-envelope binding antibodies, however, appear to have a
relatively low capacity for neutralization in cell line models [2,3,4].
In the course of natural infection, HIV-1 can induce antibody
responses to numerous well-characterized epitopes on the HIV-1
envelope glycoproteins [5]. These antibodies inhibit the virus by
various mechanisms, including classic neutralization [6], antibody-
dependent cellular cytotoxicity (ADCC) [7], antibody dependent
cell-mediated viral inhibition (ADCVI) [8], non-neutralizing HIV-
1 inhibition via Fc receptor binding (using macrophage or
dendritic cell targets) [9] and antibody-dependent complement-
mediated HIV-1 inhibition or virolysis [10]. Passive transfer
experiments have shown that certain antibodies can provide some
level of protection [11,12,13,14,15,16,17] and some studies suggest
that ‘‘multi-effector’’ polyclonal responses that have the capacity
not only to neutralize, but also to mediate ADCC or ADCVI, may
be more protective than those that mediate neutralization alone
[18]. Consequently, in hopes of eliciting sterilizing immunity, there
has been a considerable effort to develop a vaccine that will elicit
antibodies with some or all of these functions [19], and to
standardize approaches to measure these antibodies [20].
Given the lack of correlates of protection, one of the challenges
facing vaccine HIV researchers has been identifying appropriate
assays for assessing antibody responses that are surrogates for
immune protection [21]. It is generally thought that the use of
peripheral blood mononuclear cells (PBMC) for immune assays
may be more physiologic than other assay platforms that utilize
genetically engineered, recombinant reporter cell lines. However,
the inherent heterogeneity of PBMC from different individuals has
a strong impact on antibody assessment, particularly in neutral-
ization assays [22,23,24]. A myriad of factors may lead to
variability between donor PBMC used as assay target cells [25],
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represented within a given PBMC sample, as well as the potential
for certain cell subsets to differentially affect viral infection and
inhibition thereof. Increasing attention has recently been given to
innate immune cells, such as NK cells, and the role that these cells
play in HIV-1 infection [26,27,28]. Traditionally, NK cells are
involved with direct cell killing through recognition of MHC class
I complexes expressed on the surface of infected cells. However, as
NK cells also express Fc receptor on their surface, they also
function as effectors for mediating ADCC and ADCVI [29]. In
polyclonal sera or plasma, antibodies may exert various functions
depending on their specificity, avidity and ability to interact with
FcRs and complement, either separately or in concert, to influence
viral infection. Furthermore, the repertoire may be dominated by
a particular functional response which may or may not be
measured in a given assay system, depending on the cell types
present and on the nature and on the timing of virus-antibody-host
cell interactions. Thus, use of mixed effector and target cell
populations present in PBMC should have the potential to assess
multiple antibody functions.
In traditional PBMC neutralization assays employing p24
endpoints, the antibodies and viral inocula are usually washed
out after a defined period, typically ranging from 1–20 hours [30],
thereby restricting antibodies from reacting with newly infected
cells. Recently, infectious molecular clones (IMCs) that express the
Renilla reneformis luciferase gene (LucR) have been developed for
assessing HIV neutralization and antibody-mediated inhibition
[22,31]. These new tools are proving particularly informative in
assays employing PBMC targets [31]. Since the endpoint is the
measurement of luciferase activity instead of extracellular p24, the
use of LucR-expressing IMC avoids the issue of patient or
vaccinee anti-p24 antibodies complexing with extracellular p24,
and eliminates the need for cell washing [32]. This PBMC
neutralization format has a wide linear range of LucR detection,
and is more reproducible, less expensive and has greater
throughput; furthermore, the lack of virus and antibody wash-
out allows the antibodies to remain continuously present
throughout the duration of the culture [22].
Here we report that this new technology reveals a substantial
influence of NK cells and NK cell receptor genotypes in the
assessment of antibody-mediated inhibition of HIV-1. The
continuous presence of antibody may provide a platform for
dissecting the various effects of virus-antibody-host cell interac-
tions. In particular, the contribution of neutralizing versus non-
neutralizing antibody-mediated HIV inhibition may be distin-
guishable within the polyclonal response to HIV infection and to
vaccination with candidate vaccines.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki, and was approved by the
independent institutional review boards both at the Walter Reed
Army Institute of Research and the Human Subjects Review
Board of the US Army Medical Research and Materiel
Command. Each participant gave written informed consent and
completed an exam of understanding prior to engaging in any
study-related procedure.
PBMC culture and cell depletion
PBMC were cultured as previously indicated [30]. Cells were
stimulated with 1 mg/ml phytohemagglutinin (PHA) (Sigma, St.
Louis MO) and 20% IL-2 (Roche, Indianapolis IN) for 3–4 days.
Cell depletions were performed on PHA stimulated cells 3–4 days
post-stimulation. To remove NK cells, mouse anti-human CD16
and CD56 antibodies (Invitrogen, Carlsbad CA) and Dynabeads
M-280 coated with sheep anti-mouse IgG (Invitrogen, Carlsbad
CA) were used per manufacture’s instructions.
PBMC characterization
To genotype the PBMC, we used previously described high-
throughput assays for genotyping [33]. Using 8-color flow
cytometry (LSRII, BD Biosciences, San Josa CA) the percentages
of CD4+ T cells, CD8+ T cells, NK cells, B cells, and monocytes
were quantified. The following antibodies were used: CD16-FITC,
CD56-PE, CD4-ECD, CD8-PerCp-Cy5.5, CD19-APC, CD14-
Alexa 700, CD3-APC-H7, and the LIVE/DEAD Violet Viability/
Vitality kit was employed to gate on viable cells. All of the stains
are from BD Biosciences, except for CD4 ECD (Beckman Coulter,
Brea CA). Cells were first stained with the viability dye per
manufacturers instructions and then washed 2 times with staining
buffer (PBS containing 0.5% bovine serum albumin and 0.1%
sodium azide). Cells were then blocked using normal mouse IgG
(Caltag, Eugene OR) for 15 min at 4uC. Cells were then
centrifuged, supernatant was removed, and cells were resuspended
with antibody cocktail and incubated at 4uC for at least 30 min.
Analysis was performed in FloJo (Ashland, OR). For each
antibody included in the cocktail, an FMO was generated. For a
sample gating strategy, refer to Figure S1.
Virus stock production
Virus stocks from IMC were generated in either 293T cells
using FuGene 6 (Roche Applied Science) transfection or
amplification in PHA stimulated PBMC. Of these IMC, 4
contained no reporter gene [34], while the other 2 contained
Renilla luciferase [22]. For transfection, 640 ml of serum-free DMEM
and 96 ml of FuGene 6 were incubated together at room
temperature for 5 min. Then 20 mg of IMC proviral plasmid
DNA was added and the mixture was incubated at room
temperature for 30 min. The mixture was then added to a T-75
flask of 5610
6 293T cells that had been plated the previous day in
20 mls of cDMEM [DMEM, 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-gluatmine (Quality Biologics, Gaithers-
burg, MD) and 15% fetal calf serum (FCS)(Gemini-Bio,
Woodland, CA)]. The proviral DNA and FuGene6 were
incubated with the cells at 37uCi naC O 2 incubator for 6 hrs.
The media was then carefully removed and discarded. Twenty mls
of cDMEM were then added without disturbing the monolayer.
The culture was incubated for an additional 72 hrs at 37uCi na
CO2 incubator after which the supernatant was collected and
filtered through a 0.22 mm filter, aliquoted and stored in liquid
nitrogen. PBMC-passaged IMC stocks were generated as de-
scribed in [30], except instead of primary isolates, 293T IMC
stocks were used. Viral titrations were performed as described
[30]; however, non-reporter IMC, or LucR IMC [22,35] were
used in place of primary isolates. For LucR IMC, the cut off for
positive wells (used for the Spearman-Karber titer calculation) was
3 times the relative light units (RLU) for cells alone. Viral
permissivity rankings were obtained by rank ordering the day 4
p24 values of the undiluted row in the viral titrations for the IMC
without reporter genes or the day 7 relative light unit (RLU) values
of the undiluted row in the viral titrations for the IMC with Renilla
luciferase.
LucR IMC PBMC Neutralization Assay
The assay was performed as previously described [30] with
some modifications. LucR IMCs [22,35] were used in place of
NK Cells in the Assessment of HIV-1 Neutralization
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that yielded .1610
5 RLU at day 4 post-infection. Antibody and
virus were incubated together for 60 min at 37uC prior to the
addition of 1610
5 PHA-PBMC. Antibody, virus and cells were
incubated overnight at 37uC as previously described; however, the
next day, instead of washing the cells to remove antibody and any
remaining virus, 100 ml of cRPMI was added and the culture was
continued until day 4. At the day of harvest, 20 ml of lysate was
removed for measurement of luciferase activity using the Renilla
Luciferase Assay System (Promega Corp, Madison WI). Relative
light units (RLU) were read using the Victor Light luminometer
(Perkin Elmer Life Sciences, Shelton CT).
Intracellular p24 Neutralization Assay
The assay was performed as previously described [36] with
some modifications. Antibody and virus were incubated together
for 60 min at 37uC then added to PHA stimulated PBMC.
However, instead of washing cells the next day and adding the
same concentration of antibody back into the culture, the virus
and antibody were left in the culture for the 4 days of incubation,
before intracellular p24 staining was performed.
Statistical analysis
The comparisons of quartiles for permissivity and neutralization
sensitivity were performed using the The Kruskal-Wallis test. The
Wilcoxon rank test was used to determine statistical significance
between bulk and NK cell deleted PBMC. We utilized Fisher’s
exact test to determine the difference between the number of
donors in quartile 1 and 2 who had a specific polymorphism versus
those in quartile 3 and 4. Fisher’s exact test was also used to
calculate the significance between the numbers of median
neutralization titers showing stronger neutralization when one
polymorphism was present compared the other (for KIR3DS1 vs
KIR3DL1 and for FccRIIIa 158V+ vs FccRIIIa 158V2). The
Wilcoxon rank test was used to compare the individual pairs of
values for any given antibody.
Results
NK cells have been demonstrated to actively participate in viral
inhibition in vivo and in vitro [27], but the role of NK cells in
neutralization assays (using target PBMC of multiple donors)
employed for vaccine evaluation has not been well characterized.
Prior to initiating studies on the influence of NK cells in the
presence of neutralizing antibodies, it was important to establish
the impact of NK cells on viral permissivity using our collection of
HIV-seronegative PBMC donors.
The percentage of NK cells in PBMC associates inversely
with viral permissivity
The permissivity of PBMC from 25 donors was stratified by
titering 6 infectious molecular clones (IMC) on PHA-stimulated
cells. The 6 IMCs consisted of 4 IMCs with no modifications to
the genome (57143-subtype D, GS14-subtype C, GS20-
CRF01_AE, WR27-subtype B) [34] and 2 LucR IMC (NL-
LucR.T2A-BaL.ecto and NL-LucR.T2A-SF162.ecto, hereafter
called LucR-BaL and LucR-SF162) [22]. PBMC were given an
individual rank value from 1 to 25 for each set of titers for each
virus, with 1 assigned to the donor that supported the highest
HIV-1 replication (high permissivity) and 25 assigned to the donor
that supported the lowest replication (low permissivity). For each
donor the individual rank values for each of the 6 IMC were then
averaged to obtain the overall rank (Figure S2A), and the
permissivity rankings were divided into quartiles. PBMC were
then phenotyped using multicolor flow cytometry to enumerate
immune cell populations (after 3–4 days of PHA stimulation). The
percentage of NK cells within the total lymphocyte population is
presented grouped by quartile of permissivity in Figure 1A. The
plot illustrates that increased percentages of NK cells correspond-
ed with decreased viral permissivity (Kruskal-Wallis p=0.03). The
percentages of monocytes also inversely associated with permissiv-
ity (Kruskal-Wallis p=0.04, data not shown). No significant
difference was observed for CD4+ T cells and permissivity,
although there was a trend towards higher CD4+ T cells in donors
with higher HIV-1 permissivity, as might be expected (data not
shown). The percentages of B cells, CD8 T cells and NK T cells
were not significantly different in donors with different degrees of
permissivity or neutralization (data not shown).
We hypothesized that the percentage of NK cells would have an
impact on the level of neutralization measured when primary cell
populations are used. Nineteen of the 25 donors used to generate
the permissivity data shown in Figure 1A were then ranked for
neutralization titers by performing neutralization assays using a
panel of 7 different reagents, to include the 4E10, 2F5, b12, and
2G12 monoclonal antibodies (mAbs), sCD4, a USHIV+ serum
pool (subtype B), and an individual HIV+ plasma (subtype B). The
7 neutralization reagents were assayed against LucR-BaL and
LucR-SF162 with the respective virus stocks produced in 293T
cells (via transfection), as well as in PBMC (single passage-derived).
As with the permissivity assessment, to allow for direct comparison
of the various antibodies, we utilized a ranking system. The
individual neutralization titers were assigned rank values, and
donor PBMC were then ordered according to sum of the rank
values, indicating the overall potency of neutralization observed
(Figure S2B). This sum rank value was then used to separate
donors into quartiles. In contrast to the association of viral
permissivity with NK cell levels, there was no significant
association between the percentage of NK cells and neutralization
quartile ranking (Figure 1B).
Depletion of NK cells from target PBMC has a significant
impact on neutralization
The reduction of virus production is generally interpreted as the
result of direct antibody-virus interactions when neutralization is
assessed. However, for both ADCC and ADCVI, viral inhibition is
achieved through a combination of antibody and NK cell activities
[29], measured at varying effector to target cell ratios and antibody
concentrations. To quantify the influence of NK effector cells on
the measurement of antibody-mediated neutralization, we adopted
a direct approach by depleting NK cells from PBMC to assess the
effects of depletion on neutralizing titers. NK cells were depleted
from bulk PBMC and neutralization experiments were performed
comparing titers obtained on bulk versus NK-depleted target cells.
We hypothesized that if NK cells directly influenced the level of
neutralization observed, depletion of NK cells would result in a
decrease in neutralization measured. Figure 2 shows the results for
bulk vs NK-depleted PBMC from 4 donors using the neutralizing
mAbs 2G12, 4E10, and b12, and two polyclonal antibody pools
(USHIV+ and a pool of plasmas from individuals with pure
subtype C infection, designated C pool). To maximize the ability
to detect differences upon removal of NK cells, we tested LucR-
SF162, which showed the highest overall sensitivity to neutraliza-
tion. Depletion of NK cells from the PBMC prior to use in
neutralization assays resulted in a loss of measurable neutralization
amongst all 4 donors for most antibodies, with the exception of
b12 (Figure 2A). The magnitude of the reduction in 80% titer
(ID80) or increase in the 80% inhibitory concentration (IC80) after
NK cell depletion varied, with donor BC171 exhibiting the
NK Cells in the Assessment of HIV-1 Neutralization
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when using the polyclonal antibodies (Figure 2B).
Given the potent effect of NK cells observed for the polyclonal
reagents, and adopting a view towards future testing of polyclonal
vaccine sera or plasma, additional experiments were performed
using the USHIV+ serum pool and target PBMC from an
additional 14 different donors. As shown in Figure 3A, depletion of
NK cells resulted in from 1 to 3 logs reduction in neutralization of
the LucR-SF162, with a median titer (red lines) reduction of 1.5
logs. Using these 18 donors, the difference between 80%
neutralization titers obtained for USHIV+ using bulk versus
NK-depleted PBMC was highly significant (Wilcoxon rank,
p=0.0002), demonstrating a substantial impact of NK cells on
PBMC neutralization titers.
A potential role for NK receptor genetic polymorphisms
in the NK cell influence on PBMC neutralization titers
To better understand the NK cell characteristics involved in the
apparent activity of these cells in neutralization assays, the PBMC
were assessed for a panel of host genetic polymorphisms
comprising genotypes that have been shown to influence HIV-1
replication and antibody interactions in vitro. For example, donors
that were CCR5D32 homozygous were eliminated from the study,
due to extremely low permissivity. The PBMC were screened for
polymorphisms in a number of genes, including the killer
immunoglobulin receptors (KIR), and Fc gamma receptors
(FccR). Significant biologic associations with either permissivity
or neutralization were observed for certain KIR and FccR alleles,
to include KIR3DS1 and FccRIIIa, as described below.
The inhibitory KIR3DL1 and activating KIR3DS1 segregate as
alleles of the same locus. The ligands for KIR3DL1/S1 are HLA-
Figure 1. Donors with more NK cells have decreased viral growth. Donors were stratified by viral growth (A, n=25) and neutralization (B,
n=19) then separated into quartiles. The percentages of NK cells for each donor were determined from an average of 3 experiments using flow
cytometry and plotted based on quartile. The bars represent median. The Kruskal-Wallis test was used to determine statistical significance.
doi:10.1371/journal.pone.0029454.g001
Figure 2. NK cells participate in viral inhibition. PBMC from 4 donors were depleted of NK cells (white bars), and then compared with matched
bulk PBMC as targets (black bars) in neutralization assays. The IC80s (mAbs, panel A) or ID80s (polyclonal plasma, panel B) are indicated. Each bar
represents the average of 2 experiments and the error bars show the standard error of the mean.
doi:10.1371/journal.pone.0029454.g002
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interaction seen for alleles with an isoleucine at position 80 (i.e.,
Bw4-80I) than those having a threonine at that position (i.e., Bw4-
80T). The presence of both KIR3DS1 and HLA-B Bw4-80I has
been shown to provide a clinical benefit for individuals infected
with HIV-1 (reviewed in [26,27]). Additionally, the FccRIIIa
exhibits a polymorphism at amino acid position 158 that leads to
either the low affinity form (phenylalanine, F) or high affinity form
(valine, V) for binding to the constant region (Fc) of IgG1 and
IgG3. This polymorphism has been shown to have clinical
relevance for HIV-1 infection in the context of ADCVI assays
[37]. To determine the various polymorphisms, we utilized
previously described high-throughput assays for genotyping KIR
[33] and FccRs.
Given the role described for these two polymorphisms in the
literature, we assessed whether carriage of either of these
polymorphisms was affecting the magnitude of influence of NK
cells on the neutralization observed. If so, donors with carriage of
at least one KIR3DS1 allele (referred to as 3DS1+) or at least one
high affinity allele for FccRIIIa (158V/F or 158V/V, referred to
as 158V+) might: 1) exhibit a greater loss of neutralization after
NK cell depletion, and 2) exhibit higher levels of neutralization (or
overall viral inhibition) compared with donors not carrying these
alleles. To address the first possibility, the fold-loss in neutraliza-
tion after NK cell depletion was calculated for the 18 donors
presented in Figure 3A. This fold-loss was expressed as the value
obtained by dividing the titer detected using bulk PBMC by that
obtained using NK-depleted PBMC, and these values were
graphed for 3DS1+ vs 3DS12 donors (Figure 3B), and for
158V+ vs 158V2 donors (Figure 3C). The median fold-loss for
3DS1+ donors was 17.5, while the median fold-loss for 3DS12
donors was 3.8 (Figure 3B), and the median fold-loss of
neutralization for 158V+ donors was 23.2, while for 158V2
donors, it was 6.0 (Figure 3C). While not statistically significant, a
4 to 5-fold greater loss of neutralization was observed for both
3DS1+ and 158V+ donors, compared with their 3DS12 and
158V2 counterparts. These data implicate a role for these two
polymorphisms in the NK cell impact on neutralization, and
suggest that NK cells from KIR3DS1+ or FccRIIIa 158V+ donors
might exert a stronger influence on viral inhibition than donors
without those alleles, which, in this platform, would be measured
as increased neutralization titer (or decreased IC50 for mAbs).
To address the second possibility described above (ie. that
3DS1+ and/or FcgRIIIa 158V+ donors exhibit higher levels of
neutralization), Figure 4 presents the KIR and FccRIIIa
genotypes, as well as the HLA-B serotypes, for the PBMC used
for the data presented in Figure 1B. In this figure, the ranking of
donors is also shown with regard to the overall magnitude of
neutralization titers observed (as described for Figure 1B). The
upper 2 quartiles were collectively labeled ‘‘higher neutralization’’
while the lower 2 quartiles were collectively labeled ‘‘lower
neutralization’’. It is striking that the 2 upper quartiles of donors
contain all of the KIR3DS1+ donors, and this is a statistically
significant segregation (Fisher’s exact test, p=0.03). There is also a
preponderance of the high affinity FccRIIIa 158V alleles amongst
donors yielding higher neutralization titers; 80% of the PBMC
that carried at least 1 allele with V (high affinity allele) at position
158 in FccRIIIa fell into the upper 2 quartiles, as compared to
those in the bottom 2 quartiles, showing a trend for this allele
(Fisher’s exact test, p=0.07).
The KIR3DS1 and FccRIIIa 158V genetic polymorphisms
appear to influence HIV-1 neutralization using PBMC
In light of the potential influence of the KIR3DS1 and
FccRIIIa158V alleles in neutralization using these target PBMC,
we segregated the neutralization data from the reagents used to
generate the quartiles for Figure 1B, to compare donor groups
based on carriage of these two alleles. We sought to determine
whether carriage of either of these alleles is associated with the
potency of neutralization by specific antibodies. The neutralization
titers were plotted for each individual PBMC donor and each
reagent, comparing KIR3DS12 versus KIR3DS1+ donors
(Figure 5A and 5B). For both LucR-BaL, (Figure 5A) and for
LucR-SF162 (Figure 5B), 6 out of 6 antibody reagents exhibited
either lower median mAb IC50s (left panels), or higher median
50% inhibitory dilutions (ID50s) (right panels, polyclonal reagents),
indicating more potent neutralization when KIR3DS1+ donor
PBMC were used, which is a significant association (Fisher’s exact
Figure 3. Depletion of NK cells results in a significant loss of neutralization. The ID80s for Bulk PMBC and matched NK-depleted PBMC for 18
donors are displayed (A). Also displayed is the fold-loss of neutralization after NK cell depletion comparing donors who are 3DS1+ and 3DS12 (B) and
those who are FccRIIIa158V+ vs. 158V2 (C). The black lines represent the median values. Each neutralization titer is an average of 2 experiments. The
Wilcoxon rank test was used to determine statistical significance.
doi:10.1371/journal.pone.0029454.g003
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difference between 3DS12 and 3DS1+ donors approached
statistical significance for 4E10, 2F5, 2G12, against LucR-BaL
(Wilcoxon, p=0.02, p=0.03, p=0.01, respectively) and LucR-
SF162 (Wilcoxon, p=0.01, p=0.004, p=0.004, respectively).
However, considering multiple comparisons, only the 2F5 and
2G12 results for LucR-SF162 were statistically significant. The
sCD4 reagent, which lacks antibody Fc, served as a negative
control; no difference was observed between any of the genotypes
and viruses tested using sCD4 (Figure 5A, 5B, 5C and 5D).
When the neutralization titers were separated based on carriage
of FccRIIIa low affinity alleles (158V2), versus at least one high
affinity allele (158V+), PBMC from donors bearing high affinity
FccRIIIa alleles tended to exhibit lower median IC50s for the
mAbs, and higher ID50s for the polyclonal antibodies. This was
true for both viruses. Again, for LucR-BaL, (Figure 5C) and for
LucR-SF162 (Figure 5D), 6 out of 6 antibodies showed enhanced
neutralization potencies for the donor group that carried at least
one high affinity allele, also a significant association (Fisher’s exact
test, p=0.002). In terms of quantitative titer comparisons, the only
mAb that demonstrated significantly higher IC50s in 158V+
donors for both viruses was 2G12 (Wilcoxon rank, p=0.009). The
polyclonal antibodies revealed a stronger trend toward enhanced
neutralization based on carriage of FcRcIIIa158V (Figure 5C and
5D, right panels, Wilcoxon rank, p=0.015 for both polyclonal
antibodies against LucR-BaL, and p=0.009 for both polyclonal
antibodies against LucR-SF162). While these strong trends are
observed, if multiple comparisons are considered, none of the
FccRIIIa donor group differences reach statistical significance.
In addition to KIR3DS1/L1 and FccRIIIa genotyping, relevant
polymorphisms were investigated for KIR2DL2/L3 [38], FccRIIa
[37,39,40], TRIM5a [41], and APOBEC3G [42]. No significant
relationship to performance as a source of neutralization target
cells was observed within these donors for any polymorphisms
studied within these additional genes (data not shown).
To rule out any influence of the luciferase IMC assay endpoint
and to ensure that the NK cell effects observed were not specific to
subtype B viruses in these North American donor PBMC, we also
assessed HIV-1 neutralization using a CRF01_AE IMC that had
no luciferase reporter gene in the viral genome. For this IMC,
infection was detected by measuring intracellular (IC) p24 using
flow cytometry [36]. The ICp24 PBMC assay also allows for the
continual presence of antibodies throughout the assay. In this
format and with a different subtype of virus, the depletion of NK
cells also resulted in decreased neutralization for the polyclonal
USHIV+ and C pool (Figure 6A and 6C), as well as the 4E10 mAb
(Figure 6B and 6D) tested. The fold reduction in neutralization
titer observed ranged from a 1.4 to 46-fold loss in the two different
donors assessed (BC174 and BC177). Of note, donor BC177
(KIR3DS1+ and FccRIIIa 158V/V) showed much greater loss of
neutralization as compared to donor BC174 (KIR3DS12 and
FccRIIIa 158V2), particularly for the polyclonal pools.
While the PBMC virus-antibody-host cell incubation employed
in these studies is considered to be a ‘‘neutralization assay’’, NK
cell mediated ADCC and ADCVI that require NK cells to
recognize antibody bound to viral antigens exposed on the cell
surface, appear to also occur within this assay. Thus, minimizing
the time that NK cells can interact with antibody-bound surface
viral antigens should result in diminished viral inhibition observed.
Figure 7 displays the ID50 for 3 polyclonal HIV+ reagents tested
against LucR-BaL and LucR-SF162 in two different incubation
formats. Results obtained when the antibody was maintained
continuously (as was done for all other data shown in this report)
are shown in filled bars, while values observed when antibody was
removed by cell washing following the 16–20 hr infection are
shown in empty bars. A 1 to 2-log reduction in inhibitory titer was
observed when the antibody was removed after overnight
infection. Similar results with different magnitudes of titer
reductions were observed using PBMC from a second donor
(data not shown). The increase in viral inhibition observed with
prolonged antibody-virus-host cell interaction strongly suggests a
role for additional inhibitory effects beyond classical neutralization
when the antibody is maintained, further supporting a role for NK
cells in this assay format. These data demonstrating enhanced
antibody effects over time also imply a role for Fc receptor
interactions within this model system, a subject of further study in
our laboratory.
Discussion
The ability of antibodies to inhibit HIV-1 entry and
propagation in primary cells can be influenced by numerous
parameters. A confounding factor that has been underappreciated
and not well characterized is the impact of variations in the
different immune effector cells and viral target cells in mixed
PBMC populations. Here we demonstrate that NK cells exert a
critical influence on the assessment of antibody-mediated neutral-
ization when using PBMC, and that KIR and FcR polymorphisms
may contribute to this effect. In the majority of HIV-negative
donors, NK cells were potently engaged in the viral inhibition
observed in a format where antibody is continuously present. Our
findings strongly support previous observations that antibody-NK
cell interactions can play a role in the control of HIV-1 replication
[8,37,43]. Part of this control is likely due to triggering of cytokine
production in addition to direct cell killing [8,44,45]. When
antibodies form a bridge between infected target cells and an
Figure 4. Donor PBMC ranked by neutralization. PBMC from 19
donors were used as target cells for neutralization using 6 virus stocks
and 7 neutralization reagents. The ranking and separation of donors
into the upper two quartiles (‘‘High neutralization’’) and the lower two
quartiles (‘‘Low neutralization’’) is indicated, along with the genotypes
for KIR3D, HLA-B_80, and FccRIIIa 158. Red text indicates 3DS1+, Valine
(V) at FccRIIIa position 158, or licensing through HLA-B with Bw4-80I or
Bw4-80T.
doi:10.1371/journal.pone.0029454.g004
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as entry inhibition and neutralization, may be involved in viral
suppression.
In this regard, Figure 8 shows the possible influences of NK cells
and antibodies within the PBMC assay. The first (Figure 8, 1)
represents direct neutralization of virions by antibodies, which is
the most recognized activity of antibodies in this assay. Second
(Figure 8, 2), antibody binding to viral antigens (presumably env
proteins) expressed on the surface of infected cells provides an
opportunity for ADCC activity. Third, antibodies binding to viral
antigens also allow NK cells to participate in ADCVI activity,
which includes secretion of antiviral factors (Figure 8, 3). Finally,
NK cells can directly recognize and kill infected cells. This may
occur in the absence of binding antibody due to virus induced
MHC downregulation (Figure 8, 4) or potentially due to specific
HIV peptides loaded in MHC molecules [46,47]. All four
scenarios are likely to be occurring, especially when polyclonal
samples are used in this assay. Therefore, when interpreting data
from PBMC neutralization assays where antibody has been left in
the cultures, ‘‘neutralization’’ is likely an incomplete term.
Analogous to the assessment of the polyfunctionality of T cell
responses that has been utilized to monitor the potential
effectiveness of T cell immunity [48,49,50] a PBMC assay might
be utilized to dissect and monitor the ‘‘polyfunctionality’’ of the
humoral responses present in polyclonal samples from infected or
vaccinated subjects. The initial testing using bulk PBMC (wherein
all functions are registered in the ID50) may be followed by testing
of potent samples in parallel using NK-depleted PBMC or purified
CD4+ T cells, with or without antibodies washed out after
infection (ie. with or without NK or FcR effects present).
All of the donors who bore the KIR3DS1 allele and many
donors who bore the FccRIIIa 158V+ allele tended to show higher
neutralization titers (Figure 4 and Figure 5), suggesting that these
donors have a greater capacity to mediate inhibition of viral
replication in cell culture. These data support previous reports
regarding the role of the KIR alleles in HIV-1 infection [51,52].
Figure 5. Target PBMC from KIR3DS1+ and FcgRIIIa 158V+ donors show higher levels of neutralization than KIR3DS12 and FcgRIIIa
158V2. The IC50s for the mAbs and sCD4, and the ID50s for the polyclonal antibodies, are displayed for NL-LucR.T2A-BaL.ecto (A and C) and NL-
LucR.T2A-SF162.ecto (B and D). Donors were separated by the KIR3DS genotype (A and B) and the FccRIIIa 158V genotype (C and D). The inter-
quartile ranges for the KIR3DS12 and FccRIIIa 158V2 donors are displayed in blue bars while the inter-quartile range for the KIR3DS1+ and FccRIIIa
158V+ donors are displayed in red bars. The black lines within each group represent the median neutralization values, while the grey symbols
represent individual neutralization titers. Each neutralization titer is an average of 2 experiments.
doi:10.1371/journal.pone.0029454.g005
Figure 6. NK cell depletion results in loss of neutralization against a CRF01_AE virus when using a ICp24 assay format. Neutralization
was calculated employing a subtype CRF01_AE IMC (virus CM235) without a reporter gene inserted and using a flow cytometric intracellular p24
endpoint (panels A–D). The ID50s for 2 polyclonal antibody pools (A, C) or IC50s for 4E10 (B, D) are displayed for PBMC from 2 donors that were used
either in bulk (black bars) or after NK cell depletion (white bars).
doi:10.1371/journal.pone.0029454.g006
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have been shown to exhibit enhanced ability to inhibit viral
growth, as compared with cells that have only KIR3DS1 or
KIR3DL1 with or without HLA-B Bw4-80I [51], and our data are
in agreement with these in vitro observations. Precisely how specific
antibodies influence this interaction is not yet fully understood.
Interestingly, the effects that we observed appear to be
independent of potential licensing through HLA-B Bw4, contra-
dicting some findings [51,52], but in agreement with others
[53,54]. This lack of synergy between KIR3DS1 and Bw4 has also
been found to be true for HIV-exposed uninfected individuals
[55].
Genetic polymorphisms in FccRIIa have also been shown to be
associated with HIV-1 progression [39] and with pediatric HIV-1
acquisition [40]. In the VAX004 phase III clinical trial of subtype
B gp120 vaccines, polymorphisms in both FccRIIa and FccRIIIa
were associated with HIV-1 acquisition and ADCVI was inversely
correlated with the rate of HIV-1 acquisition following gp120
vaccination [37]. The presence of the high affinity allele (158V/V)
for FccRIIIa was significantly associated with increased ADCVI
and decreased acquisition [37]. In addition, it has been described
in the cancer literature that donors who carry the FccRIIIa 158V
allele demonstrate more potent ADCC against CD20+ tumor cells
[56]. In our study, we found an association of only FccRIIIa with
the potential for increased ‘‘neutralization’’ or, more appropriate-
ly, polyfunctional inhibition of HIV-1. Of note, FccRIIIa is
expressed on NK cells, while FccRIIa is not. This may partially
account for our findings.
It is interesting to note that the KIR3DS1+ donors appeared to
have enhanced neutralization with the mAbs, while the 158V+
donors had enhanced neutralization with the polyclonal antibod-
ies. This is likely to be physiologically relevant. All of the
monoclonal antibodies are IgG1, while the polyclonal antibodies
are a mixture of IgG subclasses, potentially allowing for a greater
role for FccRIIIa. The trends observed also indicate that
additional factors beyond the polymorphisms assessed may be
affecting the ability of NK cells to mediate HIV-1 inhibition.
In initiating these studies, we hypothesized that certain
phenotypic characteristics or genetic polymorphisms might
influence HIV-1 neutralization in assays using primary cells. We
sought to identify these factors as contributors to donor-dependent
variation within PBMC assays [22,23,24,57]. In addition to T
lymphocytes, three specific types of cells that might have an ability
to influence viral inhibition when antibodies are present during the
entire assay would be NK cells, monocytes and dendritic cells
(DC). We did not study DC here, as our culture conditions for the
PBMC assay do not support DC maturation and survival. With
regards to monocytes, lower levels of monocytes were noted in
stimulated PBMC from donors that supported better HIV-1
replication and there was a trend towards higher monocytes in
PBMC from donors that fell into the upper two quartiles for
neutralization ranking (data not shown). However, direct depletion
of monocytes did not lead to a consistent loss of neutralization
(data not shown), as was observed for NK cell depletions. Thus,
the role of FccR-bearing monocytes and dendritic cells remains to
be investigated.
The findings reported here extend the observations by other
investigators regarding the importance of the role of NK cells in
HIV-1 control [27,51] and in antibody-mediated HIV-1 inhibition
[43,58], and demonstrate for the first time that specific genotypes
for NK cell receptors appear to influence the level of HIV-1
inhibition observed in PBMC neutralization assays. The observa-
tion that polymorphisms in KIR and Fc receptors play a role in
the antiviral activity of NK cells (and potentially monocytes in the
case of FcRs) within PBMC assays will allow for development of
initial guidelines for donor typing and selection for optimal
functional performance. In polyclonal sera or plasma, antibodies
may exert various functions that act separately or in concert to
influence viral infection. Furthermore, this repertoire may be
dominated by a particular functional response that may or may
not be detected. Thus, in designing standardized assays for
Figure 7. Higher neutralization is observed with antibody
maintained in the assay. Using the 2 lucifease reporter IMCs (NL-
LucR.T2A-SF162.ecto and NL-LucR.T2A-BaL.ecto), the ID50s for a serum
pool (USHIV+) and 2 individual plasmas are displayed for assay formats
where the antibodies were maintained throughout the culture period
(Ab maintained, black bars) or removed after infection (Ab removed,
white bars). Each neutralization titer is an average of 2 experiments.
doi:10.1371/journal.pone.0029454.g007
Figure 8. Model for the engagement of NK cells to mediate HIV
inhibition. HIV infection and growth may be suppressed in a variety of
ways. 1) ‘‘Traditional neutralization’’ where the antibodies bind to
virions and inhibit virion attachment and/or fusion with target cells. 2)
ADCC, in which antibodies bind to viral proteins on the surface of
infected cells, enabling NK cells to engage and kill the target cells. 3)
ADCVI, which includes not only ADCC, but also the secretion of
cytokines and/or chemokines that inhibit infection. 4) Direct killing of
infected cells triggered by downregulation of HLA_A and HLA_B, loss of
inhibitory signaling, and subsequent activation of NK killing. Polymor-
phisms in the FccRIIIa may affect functions shown in 2 and 3;
polymorphisms in KIR3D may affect NK cell function diagrammed in 4.
doi:10.1371/journal.pone.0029454.g008
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vaccine assessment, it will be vital to measure antibody activity
comprehensively. One means of achieving this goal is to allow all
PBMC subsets to participate in viral inhibition, which will provide
the potential for assessing multiple antibody functions in a more
physiologic setting. Employing an assay where antibody can
remain during the culture period may be quite important. Such an
approach may contribute to the identification of additional
correlates of protection for the RV144 phase III trial [1,59] and
for future HIV-1 vaccine trials where more broad and potent
humoral immune responses are elicited.
Supporting Information
Figure S1 Gating strategy for enumerating cell popula-
tions from bulk PBMC. The percentages of CD4+ T cells,
CD8+ T cells, NK cells, B cells, and monocytes were quantified.
Please see the materials and methods for more details.
(TIF)
Figure S2 Rank values for viral permissivity (A) and
neutralization (B). For viral permissivity (A), PBMC were given
an individual rank value from 1 to 25 for each set of titers for each
of 6 IMCs, with 1 assigned to the donor that supported the highest
HIV-1 replication (high permissivity) and 25 assigned to the donor
that supported the lowest replication (low permissivity). For each
donor the individual rank values for each of the 6 IMC were then
averaged to obtain the overall rank. Each single dot within a
column represents the donors rank for a given IMC. The red bar
represents the average rank. For neutralization (B), assays were
performed using a panel of 7 different reagents, to include the
4E10, 2F5, b12, and 2G12 monoclonal antibodies (mAbs), sCD4,
a USHIV+ serum pool (subtype B), and an individual HIV+
plasma (subtype B). The 7 neutralization reagents were assayed
against LucR-BaL and LucR-SF162 with the respective virus
stocks produced in 293T cells (via transfection), as well as in
PBMC (single passage-derived). Each single dot within a column
represents the donors rank for a given reagent against a specific
virus. The red bar represents the average rank.
(TIF)
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